Tegaserod does not alter fasting or meal-induced biliary tract motilityFISHER, Robert S; THISTLE, Johnson; DONGHAM LUO et al.The American journal of gastroenterology. 2004, Vol 99, Num 7, pp 1342-1349, issn 0002-9270, 8 p.Article

Review article: tegaserod: the global experienceCHEY, W. D.Alimentary pharmacology & therapeutics. Supplement. 2004, Vol 20, Num 7, pp 15-19, issn 0953-0673, 5 p.Article

Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndromeHARISH, Kareem; HAZEENA, Kizhekkan; THOMAS, Varghese et al.Journal of gastroenterology and hepatology. 2007, Vol 22, Num 8, pp 1183-1189, issn 0815-9319, 7 p.Article

Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteersZOU, Jian-Jun; BIAN, Xiao-Jie; LI DING et al.Journal of chromatography. B. 2008, Vol 861, Num 1, pp 151-157, issn 1570-0232, 7 p.Article

Tegaserod for constipation-predominant irritable bowel syndromeKALE-PRADHAN, Pramodini B; WILHELM, Sheila M.Pharmacotherapy. 2007, Vol 27, Num 2, pp 267-277, issn 0277-0008, 11 p.Article

Electrophysiological Characterization of Isolated Human Atrial Myocytes Exposed to TegaserodSUFFREDINI, Silvia; CERBAI, Elisabetta; GIUNTI, Gabriele et al.Basic & clinical pharmacology & toxicology (Print). 2010, Vol 106, Num 5, pp 416-421, issn 1742-7835, 6 p.Article

Tegaserod Treatment for Dysmotility-Like Functional Dyspepsia : Results of two Randomized Controlled TrialsVAKIL, Nimish; LAINE, Loren; TALLEY, Nicholas J et al.The American journal of gastroenterology. 2008, Vol 103, Num 8, pp 1906-1919, issn 0002-9270, 14 p.Article

Modulation of intestinal gas dynamics in healthy human volunteers by the 5-HT₄ receptor agonist tegaserodCOLESKI, Radoslav; OWYANG, Chung; HASLER, William L et al.The American journal of gastroenterology. 2006, Vol 101, Num 8, pp 1858-1865, issn 0002-9270, 8 p.Article

Tegaserod for treating chronic constipation in elderly patientsBAUN, Ronald F; BARENHOLTZ LEVY, Hedva.The Annals of pharmacotherapy. 2007, Vol 41, Num 2, pp 309-313, issn 1060-0280, 5 p.Article

A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of Tegaserod in Patients with irritable bowel syndromeNYHLIN, H; BANG, C; ELSBORG, L et al.Scandinavian journal of gastroenterology. 2004, Vol 39, Num 2, pp 119-126, issn 0036-5521, 8 p.Article

The 5-HT₄ receptor agonist, tegaserod, is a potent 5-HT_2B receptor antagonist in vitro and in vivoBEATTIE, D. T; SMITH, J. A. M; HUMPHREY, P. P. A et al.British journal of pharmacology. 2004, Vol 143, Num 5, pp 549-560, issn 0007-1188, 12 p.Article

Effectiveness of Probiotics in the Treatment of Irritable Bowel SyndromeWILHELM, Sheila M; BRUBAKER, Christine M; VARCAK, Elizabeth A et al.Pharmacotherapy. 2008, Vol 28, Num 4, pp 496-505, issn 0277-0008, 10 p.Article

Regional gastric contractility alterations in a diabetic gastroparesis mouse model: effects of cholinergic and serotoninergic stimulationJAMES, Arlene N; RYAN, James P; CROWELL, Michael D et al.American journal of physiology. Gastrointestinal and liver physiology. 2004, Vol 50, Num 3, pp G612-G619, issn 0193-1857Article

Tegaserod maleate in the treatment of irritable bowel syndrome: A clinical reviewRIVKIN, Anastasia.Clinical therapeutics. 2003, Vol 25, Num 7, pp 1952-1974, issn 0149-2918, 23 p.Article

Tegaserod for the treatment of chronic constipation : A randomized, double-blind, placebo-controlled multinational studyKAMM, Michael A; MÜLLER-LISSNER, Stefan; HUGOT-COURNEZ, Sophie et al.The American journal of gastroenterology. 2005, Vol 100, Num 2, pp 362-372, issn 0002-9270, 11 p.Article

Safety profile of tegaserod, a 5-HT₄ receptor agonist, for the treatment of irritable bowel syndromeHASLER, William L; SCHOENFELD, Philip.Drug safety. 2004, Vol 27, Num 9, pp 619-631, issn 0114-5916, 13 p.Article

The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical studyBARDHAN, K. D; FORBES, A; MARSDEN, C. L et al.Alimentary pharmacology & therapeutics. 2004, Vol 20, Num 2, pp 213-222, issn 0269-2813, 10 p.Article

Probiotics and functional abdominal bloatingDI STEFANO, M; MICELI, E; ARMELLINI, E et al.Journal of clinical gastroenterology. 2004, Vol 38, Num 6, pp 102-103, issn 0192-0790, 2 p., SUPConference Paper

Review article: tegaserod for chronic constipationJOHANSON, J. F.Alimentary pharmacology & therapeutics. Supplement. 2004, Vol 20, Num 7, pp 20-24, issn 0953-0673, 5 p.Article

Serotonergic modulation of visceral sensation: lower gutCAMILLERI, M.Gut. 2002, Vol 51, pp 81-86, issn 0017-5749, SUP1Conference Paper

In vitro metabolism of tegaserod in human liver and intestine: Assessment of drug interactionsVICKERS, Alison E. M; ZOLLINGER, Markus; DANNECKER, Robert et al.Drug metabolism and disposition. 2001, Vol 29, Num 10, pp 1269-1276, issn 0090-9556Article

Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndromeTOUGAS, G; SNAPE, W. J; OTTEN, M. H et al.Alimentary pharmacology & therapeutics. 2002, Vol 16, Num 10, pp 1701-1708, issn 0269-2813, 8 p.Article

Long-Term Tegaserod Treatment for Dysmotility-like Functional Dyspepsia: Results of Two Identical 1-year Cohort StudiesCHEY, William D; HOWDEN, Colin W; TACK, Jan et al.Digestive diseases and sciences. 2010, Vol 55, Num 3, pp 684-697, issn 0163-2116, 14 p.Article

Development and Evaluation of a pH-Dependent Sustained Release Tablet for Irritable Bowel SyndromeZHANG, Shuang-Qing; RAHMAN, Ziyaur; THUMMA, Sridhar et al.Drug development and industrial pharmacy. 2009, Vol 35, Num 1, pp 57-64, issn 0363-9045, 8 p.Article

Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndromeKHOSHOO, V; ARMSTEAD, C; LANDRY, L et al.Alimentary pharmacology & therapeutics. 2006, Vol 23, Num 1, pp 191-196, issn 0269-2813, 6 p.Article